Yükleniyor... / Loading...
Pharmacogenetics of Metformin Action in PCOS
Bu çalışma, polikistik over sendromu (polycystic ovary syndrome, PKOS) olan kadınlarda Metformin 500 mg tabletin etkisini ve bu etkinin genetik farklılıklarla ilişkisini incelemiştir. Çalışmaya, Rotterdam kriterlerine göre PKOS tanısı almış 18-45 yaş arası premenopozal kadınlar katılabilmiştir. Virginia Commonwealth University tarafından yürütülen çalışma faz uygulanmayan türde olup tamamlanmıştır.
Yukarıdaki özet, resmî kaydın sade dile aktarılmış halidir. Orijinal İngilizce başlık referans için gösterilir.
Kriterler ClinicalTrials.gov kaydından orijinal İngilizce haliyle alınmıştır. Uygunluk kararını yalnızca deneyi yürüten ekip verebilir.
Inclusion Criteria: * Premenopausal women between 18-45 years of age and BMI less than 42 * Diagnosed with PCOS as defined by the Rotterdam criteria, which is a combination of any two of the following three criteria: 1) chronic oligo- or amenorrhea (\<8 menstrual periods annually); 2) biochemical or clinical androgen excess; and 3) polycystic ovaries on ultrasonography -Normal thyroid function tests and serum prolactin; and exclusion of 21 alpha hydroxylase deficiency by a fasting 17 alpha hydroxyprogesterone less than 200 ng/dl -In acceptable health on the basis of interview, medical history, physical examination, and laboratory tests (CBC, SMA20,urinanalysis) -Able to provide signed, witnessed informed consent -Able to comply with study requirements Exclusion Criteria: -Diabetes mellitus by fasting glucose or OGTT, or clinically significant pulmonary, cardiac,renal,hepatic,neurologic,psychiatric,infectious,neoplastic and malignant disease (other than non-melanoma skin cancer) -Current use of oral contraceptives; use of fertility drugs within 6 months of study -Current or recent use (within 3 months prior to study entry) of metformin -Documented or suspected recent (within one year)history of drug abuse or alcoholism -Ingestion of any investigational drug within two months prior to study onset.